非酒精性脂肪性肝炎患者报告结局评分降低与纤维化程度相关
基于STELLAR临床试验中1667例NASH伴桥接纤维化或代偿性肝硬化患者,治疗前完成PRO问卷。与F3纤维化相比,F4纤维化患者在多个SF-36、CLDQ-NASH和EQ-5D领域评分更低,肝硬化、女性、高BMI、吸烟史和糖尿病等与较低PRO评分独立相关。
要点
- NASH伴F4纤维化患者较F3者在多数CLDQ-NASH领域及SF-36的Role Physical、Bodily Pain、Social Functioning领域和EQ-5D评分更低。
- NASH患者生理健康相关PRO评分显著低于一般人群,F4者6/8个SF-36领域降低4.4%至12.9%,F3者4/8个领域降低3.9%至11.7%。
- 肝硬化、女性、较高BMI、吸烟史及糖尿病或其他合并症与较低PRO评分独立相关。
核心结论
- 参与STELLAR临床试验的NASH伴进展性纤维化患者PRO评分显著降低。
- NASH患者的治疗应不仅关注改善临床结局,还应关注可量化的症状负担和健康相关生活质量。
研究设计与样本
- 分析3期STELLAR试验(NCT03053050和NCT03053063)中1667例NASH伴桥接纤维化或代偿性肝硬化(Metavir评分F3或F4)患者的数据。
- 患者年龄58±9岁,男性占40%,肝硬化占52%,糖尿病占74%。
- 患者在开始治疗前完成PRO问卷(SF-36、CLDQ-NASH、EQ-5D或WPAI:SHP)。
主要发现
- 与F3纤维化患者相比,F4纤维化患者中女性、白人、有更多血液学和胃肠道合并症及2型糖尿病的比例更高(P≤.01)。
- F4纤维化患者6/8个SF-36领域评分较一般人群降低4.4%至12.9%,F3纤维化患者4/8个领域降低3.9%至11.7%(P<.01)。
- 与F3纤维化患者相比,F4纤维化患者在CLDQ-NASH除1个领域外的所有领域、SF-36的Role Physical、Bodily Pain和Social Functioning领域及EQ-5D评分更低(P≤.01)。
- 多变量回归分析中,与较低PRO评分独立相关的因素包括肝硬化、女性、较高体重指数、吸烟史及糖尿病或其他合并症(P<.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patient-reported outcomes (PROs) are used to measure patients' experience with their disease. However, there are few PRO data from patients with NASH. We collected data from the STELLAR clinical trials to assess PROs for NASH and advanced fibrosis. METHODS: We analyzed data from 1667 patients (58 ± 9 years, 40% male, 52% with cirrhosis, 74% with diabetes) with NASH and bridging fibrosis or compensated cirrhosis (metavir scores, F3 or F4) enrolled in the phase 3 STELLAR trials of selonsertib (NCT03053050 and NCT03053063) who completed PRO questionnaires (SF-36, CLDQ-NASH, EQ-5D, or WPAI:SHP) before treatment initiation. RESULTS: Compared with patients with F3 fibrosis, higher proportions of patients with F4 fibrosis were female, were white, had more hematologic and gastrointestinal comorbidities, and had type 2 diabetes (P ≤ .01). Mean physical health-related PRO scores were significantly lower than those of the general population: patients with F4 fibrosis had score reductions of 4.4% to 12.9% in 6/8 SF-36 domains and patients with F3 fibrosis had score reductions of 3.9% to 11.7% in 4/8 domains (P < .01). Compared to patients with F3 fibrosis, those with F4 fibrosis had lower scores in all but 1 domains of CLDQ-NASH, Role Physical, Bodily Pain, and Social Functioning domains of the SF-36, and EQ-5D (P ≤ 01). In multivariate regression analysis, factors independently associated with lower PRO scores included having cirrhosis, female sex, higher body mass index, history of smoking, and diabetes or other comorbidities (P < .01). CONCLUSIONS: PROs are significantly lower in patients with NASH with advanced fibrosis who participated in the STELLAR clinical trials. Treatment of patients with NASH should focus on improving not only clinical outcomes but also quantifiable symptom burden and health-related quality of life.
引用
- Younossi ZM, Stepanova M, Anstee QM, et al. Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2019. PMID: 30779990. doi:10.1016/j.cgh.2019.02.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。